Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Understanding Task Force Draft Recommendations This fact sheet explains the Task Force’s draft recommendation statement on screening for skin cancer. It also tells you how you can send comments about the draft recommendation to the Task Force. Comments may be submitted from December 1 to December 28, 2015. The Task Force welcomes your comments. Screening for Skin Cancer The U.S. Preventive Services Task Force (Task Force) has issued a draft recommendation statement on Screening for Skin Cancer. This draft recommendation statement applies to adults who do not have any signs or symptoms of skin cancer and who do not have a history of skin cancer. It does not apply to adults who have developed abnormal skin changes or to those who are already under a doctor’s care because they are at high risk of developing skin cancer. Individuals who have concerns about their skin should talk with their doctor. What is skin cancer? The draft recommendation statement summarizes what the Task Force learned about the potential benefits and harms of screening for skin cancer, specifically for melanoma: There is not enough evidence on the benefits and harms of routine visual skin examinations by a doctor to recommend for or against this skin cancer screening test in adults who have no signs or symptoms of skin cancer. Skin cancer is cancer that occurs in different kinds of cells in the epidermis, the outer layer of the skin. The three main types of skin cancer are melanoma, basal cell carcinoma, and squamous cell carcinoma. Facts About Skin Cancer Skin cancer is the most common type of cancer in the United States. Two types—basal cell and squamous cell—make up 97% of all skin cancers. These types of skin cancer, which rarely cause death, are also called nonmelanoma skin cancer. The third main kind of skin cancer is melanoma. Only about 3% of skin cancers are melanoma, but it is much more likely to result in death than nonmelanoma skin cancer. In 2015, 74,000 adults in the United States will develop melanoma and nearly 10,000 will die from the disease. Like many cancers, the risk of melanoma increases with age. Skin cancer of any type occurs more commonly in men than in women, and among individuals who: • Have blonde or red hair, light eye color, and fair skin that freckles and sunburns easily • Use indoor tanning beds • Have a past history of sunburns or skin cancer • Have a family history of melanoma Additional factors that place an individual at high risk of developing melanoma include having abnormal moles and having more than 100 moles. Comment Period from December 1 to December 28, 2015. Task Force DRAFT Recommendation | 1 Screening for Skin Cancer The usual way doctors screen for any type of skin cancer is a visual skin examination to look for moles and other spots with color different from the rest of the skin. In this exam, doctors follow the ABCDE rule to look for the following: • A = asymmetry (one half of the mole does not match the other half) • B = border irregularity (edges of the mole are ragged, notched, or blurred) • C = color (color of the mole is not uniform, with different shades of tan, brown, or black) • D = diameter of more than 1/4 inch (about the size of a pencil eraser) • E = evolving (the mole is changing over time) Doctors may also use a dermascope, which is like a magnifying lens with a bright light attached to it, to further inspect the mole or spot. Sometimes, they use whole body photography to assess changes in the growth. Potential Benefits and Harms of Skin Cancer Screening In its examination of the evidence, the Task Force focused on whether a visual skin cancer examination by a doctor can ultimately reduce illness and deaths from melanoma, the most serious form of skin cancer. It also looked at possible harms from the screening itself as well as any procedures that occur as a result of the screening. The Task Force found there is not enough evidence to know for certain whether a visual skin cancer screening examination by a doctor reduces deaths from melanoma. It also did not find much information about harms of screening. Potential harms include unnecessary procedures (such as a skin biopsy or excision) for lesions that do not turn out to be cancer, or for skin cancers that would never have gone on to harm the person or result in death. A biopsy involves taking a sample of tissue to examine it more closely for possible cancer. Biopsies and excisions may have harms, such as poor cosmetic outcomes, or, rarely, scarring or other problems that interfere with feeling or ability to move a part of the body. Because of this lack of information, the Task Force is calling for more research to better understand the balance of potential benefits and harms of visual skin cancer examinations for melanoma screening. The Draft Recommendation on Screening for Skin Cancer: What Does It Mean? Here is the Task Force’s draft recommendation on screening for skin cancer. The grade is based on the quality and strength of the evidence about the potential benefits and harms of the screening. Task Force recommendation grades are explained in the box at the end of this fact sheet. When there is not enough evidence about a screening test to judge benefits and harms, the Task Force does not make a recommendation for or against the test—it issues an I Statement. The Notes explain key ideas. Before you send comments to the Task Force, you may want to read the full draft recommendation statement. The recommendation statement explains the evidence the Task Force reviewed and how it decided on the grade. An evidence report provides more detail about the studies the Task Force reviewed. Comment Period from December 1 to December 28, 2015. Task Force DRAFT Recommendation | 2 Screening for Skin Cancer Notes 1 The Task Force concludes that the current evidence is insufficient to assess the balance of benefits and harms of visual skin cancer screening in adults. I Statement 1 current evidence is insufficient The Task Force did not find enough information to know whether this screening test can prevent deaths from melanoma. visual skin cancer screening An examination in which a doctor looks at a person’s skin to assess whether there are any abnormal growths or other changes that might suggest skin cancer. adults For purposes of this recommendation statement, adults means people ages 18 and older who do not have any signs or symptoms of skin cancer and who do not have a history of skin cancer. It does not apply to adults who have developed abnormal skin changes or to those who are already under a doctor’s care because they are at high risk of developing skin cancer. Comment Period from December 1 to December 28, 2015. Task Force DRAFT Recommendation | 3 Screening for Skin Cancer What is the U.S. Preventive Services Task Force? The Task Force is an independent, volunteer group of national experts in prevention and evidence-based medicine. The Task Force works to improve the health of all Americans by making evidence-based recommendations about clinical preventive services, such as screenings, counseling services, and preventive medicines. The recommendations apply to people with no signs or symptoms of the disease being discussed. To develop a recommendation statement, Task Force members consider the best available science and research on a topic. For each topic, the Task Force posts draft documents for public comment, including a draft recommendation statement. All comments are reviewed and considered in developing the final recommendation statement. To learn more, visit the Task Force Web site. Task Force Recommendation Grades Grade Take Steps to Prevent Skin Cancer (healthfinder.gov) Skin Cancer (National Cancer Institute) Melanoma (Medline Plus) Definition A Recommended. B Recommended. C Recommendation depends on the patient’s situation. D Not recommended. I statement Click Here to Learn More About Skin Cancer There is not enough evidence to make a recommendation. Click Here to Comment on the Draft Recommendation December 1 December 28, 2015 The Task Force welcomes comments on this draft recommendation. Comments must be received between December 1 and December 28, 2015. Comment Period from December 1 to December 28, 2015. All comments will be considered for use in writing final recommendations. Task Force DRAFT Recommendation | 4